Calamos Advisors LLC Summit Therapeutics Inc. Transaction History
Calamos Advisors LLC
- $16.1 Billion
- Q3 2024
A detailed history of Calamos Advisors LLC transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Calamos Advisors LLC holds 46,747 shares of SMMT stock, worth $872,766. This represents 0.01% of its overall portfolio holdings.
Number of Shares
46,747Holding current value
$872,766% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding SMMT
# of Institutions
192Shares Held
75.8MCall Options Held
2.01MPut Options Held
2.84M-
Baker Bros. Advisors LP New York, NY24.4MShares$456 Million5.73% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.9MShares$204 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$147 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.44MShares$102 Million0.01% of portfolio
-
State Street Corp Boston, MA3.47MShares$64.8 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $3.76B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...